Keywords: genentech, 1st, qtr, product, sales, leap, first-quarter
Genentech's 1st qtr product sales leap 42%
Article | 15 April 1999
First-quarter 1999 revenues at Genentech grew 22% to $322.3 million,with product sales up 42% at $234.1 million, driven by Herceptin (trastuzumab) and Rituxan (rituximab). ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
